A savvy clinical trialist may want to know the robustness (or fragility) of the mortality benefit of
Equally foolish is to ignore the wealth of data supporting clear impact on death and/or MI with improvements in medical therapies and stent technology. Whether a BARI-2D-guided approach or an "ISCHEMIA"-guided approach or a "FREEDOM"
trial-guided approach is considered, the optimal management of patients with diabetes and multivessel disease should be individualized using a heart team to weigh the upfront risk of CABG with potential late benefits, ability to completely revascularize with PCI, ability of patient to be compliant with medication therapies, and most importantly, patient preference.
